• Labelling Solution Offers an Instant Validated Platform for COVID-19 Clinical Trials   
  • Warren Stacey, PRISYM ID.

Laboratory Products

Labelling Solution Offers an Instant Validated Platform for COVID-19 Clinical Trials   

Apr 08 2020

PRISYM ID, a leading provider of data-led label and artwork management solutions today announced its PRISYM 360 SaaS clinical trials labelling solution is live with customers and available to those pharmaceutical and trials organisations who need quick entry to clinical label printing.

To support the life sciences sector’s response to Covid-19, PRISYM ID is offering a cloud-based, ready to use version of its clinical trials SaaS labelling platform including a pre-validated pack with industry standard print processes.  It is fast to onboard, needs minimal IT input to set up and provides certainty to the market in these uncharted times.

Being pre-validated, the application removes a significant proportion of the cost, time and risk associated with implementing and validating a labelling system. It provides organisations with the control and agility needed to remove risk for clinical trial printing processes.

Key features of this version include: role based security controls; printer agnostic label designs; clinical trial filtered study and sequenced printing (Clinical Trial Supply); product label printing; comprehensive, secure audit log including the ability to transfer content and templates to different organisations as the trial grows; language management controls; version and state control of all design and content elements; version and state control of data models and workflows; workflow templates; clinical trial data management, including the import and management of randomised data; extensive barcode symbology support, including GS1 Clinical Trials; hosted through a fully validated and compliant cloud environment.

Warren Stacey, SVP of Sales at PRISYM ID, commented: “With the life science industry working at exceptional speed to run trials and accelerate the speed at which they come to market, labelling may be something of an afterthought. Yet it is critical to the process. Generic labelling software may be a blunt tool when it comes to validation, version control, compliance and navigating the nuances of the clinical trials supply chain. Our PRISYM 360 SaaS solution already has customers live in this space and it offers clinical researchers an off-the-shelf platform that’s fit for purpose, validated and secure.”

Warren continued: “To help the cause, we are offering organisations who are responding to Covid-19 special provisions to speed up their ability to get access to the solution, with environments being set up in advance and a team waiting to onboard them. A process that may normally take months has been reduced to days.”  

More information online 

 


Digital Edition

LabAsia Buyers Guide 2021

October 2021

In this Edition Articles - Applications of Newly Developed 2.7 μm Porous Graphitic Carbon Particles in U/HPLC - Improve sensitivity and decrease matrix effects in pesticide residue analysis...

View all digital editions

Events

ASMS Conference - NEW DATES

Oct 31 2021 Philadelphia, PA, USA

analytica Lab Africa -CANCELLED

Nov 02 2021 Johannesburg, South Africa

Lab Innovations 2021

Nov 03 2021 Birmingham, UK

ISPPP 2021

Nov 07 2021 Porto, Portugal

JASIS 2021

Nov 08 2021 Chiba, Japan

View all events